BSX Stock Crashes To 4-Year Lows: Boston Scientific Sees Q4 Sales Declining, CEO Remains Confident In ‘Long-Term Strategy’

For full year 2026, Boston Scientific expects reported sales growth of about 4.25%, down from its previous forecast of 5.5% to 6.5%
A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024. (Photo by Erica Denhoff/Icon Sportswire via Getty Images)
A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024. (Photo by Erica Denhoff/Icon Sportswire via Getty Images)
Profile Image
Arnab Paul·Stocktwits
Published Oct 28, 2026   |   10:36 AM EDT
Share
·
Add us onAdd us on Google
Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...
  • The company lowered its full-year adjusted earnings outlook to $3.16 to $3.18 per share, down from $3.28 to $3.32 per share.
  • Q3 net sales rose 1.5% to $5.14 billion, exceeding Wall Street estimates of $5.04 billion, according to Fiscal.ai
  • Q4 net sales is expected to decline between 1% and 3% from a year earlier.

Advertisement|Remove ads.

Shares of Boston Scientific (BSX) tumbled 8% on Wednesday and hit their lowest level since October 2022 earlier in the session after the medical device maker lowered its annual sales outlook and said it expects fourth-quarter revenue to decline.

BSX shares are on track for their fifth loss in six sessions.

Boston Scientific Cuts Q4 Sales Forecast

Boston Scientific said it expects fourth quarter (Q4) net sales to decline between 1% and 3% from a year earlier. For full year 2026, the company expects reported sales growth of about 4.25%, down from its previous forecast of 5.5% to 6.5%. Organic sales growth is projected at 3.75%, down from an earlier estimate of 5% to 6%.

Advertisement|Remove ads.

The company also lowered its full-year adjusted earnings outlook to $3.16 to $3.18 per share, down from $3.28 to $3.32 per share.

Cybersecurity Attack To Disrupt FY 2026 Financial Performance

In August, Boston Scientific disclosed a cybersecurity incident that disrupted manufacturing, order processing, and shipments globally. The company subsequently warned that the disruptions would materially affect its 2026 financial performance, although it expected to recover some lost revenue as operations gradually resumed.

On Wednesday, CEO Mike Mahoney acknowledged the difficult year but said he remained “confident in our long-term strategy,” citing the company’s product portfolio and pipeline of new technologies.

Advertisement|Remove ads.

Meanwhile, Q3 net sales rose 1.5% to $5.14 billion, exceeding Wall Street estimates of $5.04 billion, according to Fiscal.ai. Adjusted earnings per share slipped to $0.73 from $0.75 last year, but narrowly beat consensus estimates of $0.72 per share.

Retail Turns Bullish On BSX

Despite the slump, retail sentiment surrounding BSX on Stocktwits flipped to ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.

BSX.png

Advertisement|Remove ads.

The stock has been under strong selling pressure so far this year, crashing more than 56%.

Also read: WEN Stock Surges 15% As Trian Fund Offers $1.4B To Take The Burger Chain Private

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Advertisement|Remove ads.

Comments
Share your thoughts...

Comments posted here will also appear on symbol pages.

Follow on Google News
Read about our editorial guidelines and ethics policy

Advertisement|Remove ads.